Replimune Group, Inc. - 8-K Filing
FDA advisory committee voted 10 to 3 that efficacy results from IGNYTE study for RP1 in advanced melanoma are evaluable and clinically meaningful
Tickers: $REPL
More Regulatory news
- Future Vision II Acquisition Corp. - 10-Q Filing
- THUNDER MOUNTAIN GOLD INC - 10-Q Filing
- MiNK Therapeutics, Inc. - 8-K Filing
- SusGlobal Energy Corp. - 10-Q Filing
- Ideal Power Inc. - 8-K Filing
- DIGI INTERNATIONAL INC - 8-K Filing
- ZeroStack Corp. - 8-K Filing
- Sound Point Meridian Capital, Inc. - 8-K Filing
- Boost Run Inc. - 8-K Filing
- INTERFACE INC - 8-K Filing